Barclays analyst says outcome is worst for Amgen
A Barclays analyst, Emily Field, said the Novartis heart-disease drug announcement was “the worst possible outcome for Amgen,” adding it cast doubt on one of Amgen’s major drugs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.